|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0018759,
umls-concept:C0030193,
umls-concept:C0030705,
umls-concept:C0184511,
umls-concept:C0205177,
umls-concept:C0205485,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0332293,
umls-concept:C0442027,
umls-concept:C0597721,
umls-concept:C1274040,
umls-concept:C1313458,
umls-concept:C1527415,
umls-concept:C1999216
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-1-28
|
|
pubmed:abstractText |
To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a tumour necrosis factor alpha inhibitor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1468-2060
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
413-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19587388-Antirheumatic Agents,
pubmed-meshheading:19587388-Arthritis, Rheumatoid,
pubmed-meshheading:19587388-Dose-Response Relationship, Drug,
pubmed-meshheading:19587388-Epidemiologic Methods,
pubmed-meshheading:19587388-Female,
pubmed-meshheading:19587388-Humans,
pubmed-meshheading:19587388-Janus Kinase 3,
pubmed-meshheading:19587388-Male,
pubmed-meshheading:19587388-Middle Aged,
pubmed-meshheading:19587388-Pain,
pubmed-meshheading:19587388-Pain Measurement,
pubmed-meshheading:19587388-Protein Kinase Inhibitors,
pubmed-meshheading:19587388-Pyrimidines,
pubmed-meshheading:19587388-Pyrroles,
pubmed-meshheading:19587388-Recovery of Function,
pubmed-meshheading:19587388-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Pfizer Inc, Ann Arbor, Michigan, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
